Health
Canopy Biosciences develops spatial proteomics assay for COVID-19 – News-Medical.Net
Canopy Biosciences, a Bruker Company, today announced the successful development of a new assay for examining immune response to COVID-19.
Canopy Biosciences, a Bruker Company, today announced the successful development of a new assay for examining immune response to COVID-19. The assay uses high-plex spatial proteomics and is performed on Canopy’s ZellScannerONE precise spatial phenotyping instrument. ZellScannerONE enables multiplexed spatial quantification of protein biomarkers in tissue samples, as well as in suspended cells. Relative to traditional techniques, such as flow cytometry, Canopy’s ChipCytometry is able to detect and…
-
Noosa News23 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General18 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
General23 hours agoOlder Aussies back increased superannuation tax
-
Noosa News20 hours agoTips to improve engagement – Proctor